Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukemia, and systemic mastocytosis

被引:50
作者
Bain, BJ [1 ]
机构
[1] Univ London Imperial Coll Sci Technol & Med, St Marys Hosp, Fac Med, Dept Hematol, London, England
关键词
D O I
10.1002/ajh.20088
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Chronic eosinophilic leukemia is a neoplastic condition with persistent eosinophilia as the major hematological abnormality and with the eosinophils being part of the neoplastic clone. Some cases can be recognized by traditional hematological criteria, but many can be recognized only when a clonal cytogenetic or molecular genetic abnormality is demonstrated. A range of cytogenetic and molecular genetic abnormalities has been recognized, including both those seen in other myeloid malignancies (such as trisomy 8, monosomy 7, and 20q-) and those that are particularly linked to eosinophil differentiation (such as rearrangements of PDGFRB, FGFR1, and PDGFRA, the latter with formation of a FIP1L1-PDGFRA fusion gene). The discovery of the FIP1L1-PDGFRA fusion gene has led to the recognition that many patients who would previously have been regarded as having idiopathic hypereosinophilia actually have chronic eosinophilic leukemia. The same fusion gene has also been found in patients with hypereosinophilia and atypical bone marrow mast cells but whether this syndrome should be regarded as a variant of eosinophilic leukemia or as a variant of systemic mastocytosis remains to be established. (C) 2004 Wiley-Liss, Inc.
引用
收藏
页码:82 / 85
页数:4
相关论文
共 18 条
[1]  
Bain B, 2004, HAEMATOLOGICA, V89, P133
[2]   Cytogenetic and molecular genetic aspects of eosinophilic leukaemias [J].
Bain, BJ .
BRITISH JOURNAL OF HAEMATOLOGY, 2003, 122 (02) :173-179
[3]   HYPEREOSINOPHILIC SYNDROME - ANALYSIS OF 14 CASES WITH REVIEW OF LITERATURE [J].
CHUSID, MJ ;
DALE, DC ;
WEST, BC ;
WOLFF, SM .
MEDICINE, 1975, 54 (01) :1-27
[4]   PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease [J].
Cools, J ;
Stover, EH ;
Boulton, CL ;
Gotlib, J ;
Legare, RD ;
Amaral, SM ;
Curley, DP ;
Duclos, N ;
Rowan, R ;
Kutok, JL ;
Lee, BH ;
Williams, IR ;
Coutre, SE ;
Stone, RM ;
DeAngelo, DJ ;
Marynen, P ;
Manley, PW ;
Meyer, T ;
Fabbro, D ;
Neuberg, D ;
Weisberg, E ;
Griffin, JD ;
Gilliland, DG .
CANCER CELL, 2003, 3 (05) :459-469
[5]   A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome [J].
Cools, J ;
DeAngelo, DJ ;
Gotlib, J ;
Stover, EH ;
Legare, RD ;
Cortes, J ;
Kutok, J ;
Clark, J ;
Galinsky, I ;
Griffin, JD ;
Cross, NCP ;
Tefferi, A ;
Malone, J ;
Alam, R ;
Schrier, SL ;
Schmid, J ;
Rose, M ;
Vandenberghe, P ;
Verhoef, G ;
Boogaerts, M ;
Wlodarska, I ;
Kantarjian, H ;
Marynen, P ;
Coutre, SE ;
Stone, R ;
Gilliland, DG .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (13) :1201-1214
[6]   The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins [J].
Demiroglu, A ;
Steer, EJ ;
Heath, C ;
Taylor, K ;
Bentley, M ;
Allen, SL ;
Koduru, P ;
Brody, JP ;
Hawson, G ;
Rodwell, R ;
Doody, ML ;
Carnicero, F ;
Reiter, A ;
Goldman, JM ;
Melo, JV ;
Cross, NCP .
BLOOD, 2001, 98 (13) :3778-3783
[7]   17-allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells [J].
Fumo, G ;
Akin, C ;
Metcalfe, DD ;
Neckers, L .
BLOOD, 2004, 103 (03) :1078-1084
[8]  
Gotlib J, 2003, BLOOD, V102, p919A
[9]   Cytogenetic and molecular genetic abnormalities in systemic mastocytosis [J].
Gupta, R ;
Bain, BJ ;
Knight, CL .
ACTA HAEMATOLOGICA, 2002, 107 (02) :123-128
[10]   Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome [J].
Klion, AD ;
Robyn, J ;
Akin, C ;
Noel, P ;
Brown, M ;
Law, M ;
Metcalfe, DD ;
Dunbar, C ;
Nutman, TB .
BLOOD, 2004, 103 (02) :473-478